Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(75.0%)
Phase 4
2(25.0%)
8Total
N/A(6)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT06776549Not ApplicableRecruiting

Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest

Role: lead

NCT02588001Not ApplicableCompleted

Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide

Role: collaborator

NCT05071950Not ApplicableCompleted

The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting

Role: collaborator

NCT02329132Completed

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

Role: lead

NCT02328157Not ApplicableUnknown

Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.

Role: lead

NCT02321267Phase 4Unknown

Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Role: lead

NCT02318641Unknown

Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap

Role: lead

NCT02988999Not ApplicableUnknown

Efficacy of D-allulose on Weight and Fat Loss and Insulin Resistance in Non-diabetic Obese Subjects

Role: collaborator

NCT02455934Not ApplicableCompleted

Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level

Role: collaborator

NCT01381913Completed

Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer

Role: lead

NCT01184599Phase 4Unknown

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

Role: lead

All 11 trials loaded